Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
GlaxoSmithKline has agreed to pay $229 million to settle lawsuits brought by eight U.S. states related to improper marketing of its Avandia diabetes drug, the British drugmaker said on Wednesday. The company, in a regulatory filing, said the settlement was within provisions it had previously set aside for litigation. The agreement also encompasses allegations brought by Louisiana’s attorney general involving other Glaxo products, the company said.
Help employers find you! Check out all the jobs and post your resume.